Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

Active:	No
Cancer Type:	Brain & Spinal Cord Tumor	NCT ID:	NCT02840409
Trial Phases:	Phase II	Protocol IDs:	1000052116 (primary) NCI-2018-02047
Eligibility:	6 Months - 18 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Hospital for Sick Children
NCI Full Details:	http://clinicaltrials.gov/show/NCT02840409

Summary

This is an open-label, randomized, multi-center, comparator Phase II trial looking at the
addition of Bevacizumab to Vinblastine in chemotherapy naïve pediatric patients with
progressive Low Grade Glioma aged 6 months to less than18 years of age at the time of
initiation of therapy. Participants will be randomized to Arm A or Arm B. Arm A includes 68
weeks of single agent Vinblastine administered once weekly IV. Arm B includes 68 weeks of
Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered
every two weeks IV for the initial 24 weeks. Randomization will take place at the time of
registration taking into account NF1 and BRAF-KIAA1549-fusion status.

Treatment Sites in Georgia

Aflac Cancer and Blood Disorders Center of Children’s at Egleston
1405 Clifton Road NE
3rd Floor
Atlanta, GA 30322
404-785-0853
www.choa.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.